Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Rating of “Buy” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given an average rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and two have assigned a strong buy recommendation to the company.

BAYRY has been the topic of a number of recent research reports. Jefferies Financial Group raised Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd.

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $13.84 on Monday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. The stock has a 50-day simple moving average of $13.03 and a 200 day simple moving average of $12.18. The stock has a market capitalization of $54.39 billion, a PE ratio of -27.14, a P/E/G ratio of 4.34 and a beta of 0.55. Bayer Aktiengesellschaft has a twelve month low of $7.48 and a twelve month high of $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.06. The company had revenue of $12.53 billion during the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Research analysts anticipate that Bayer Aktiengesellschaft will post 1.28 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.